This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

White House again weighs in with US high court on ‘skinny label’ infringement

By Nick Robertson ( December 16, 2025, 20:19 GMT | Comment) -- With the US solicitor general urging the Supreme Court this month to grant certiorari in Hikma Pharmaceuticals’ appeal of an induced infringement verdict over a generic drug’s “skinny label,” both US political parties have now encouraged the court to address the issue. It represents a bipartisan focus on lowering drug prices through patent law, attorneys told MLex.The US solicitor general’s request that the Supreme Court review a dispute between Hikma Pharmaceuticals and Amarin Pharma over generic drug “skinny labels” this month shows a bipartisan focus on reducing drug prices through patent law....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login